Jiajia Song1, Ling Bai1, Jianzhao Zhai1, Zhaodan Xin1, Liting You1, Yi Zhou1, Juan Zhou2, Binwu Ying3. 1. Department of Laboratory Medicine, West China Hospital, Sichuan University, Chendu, Sichuan, China. 2. Department of Laboratory Medicine, West China Hospital, Sichuan University, Chendu, Sichuan, China. zhoujuan39@qq.com. 3. Department of Laboratory Medicine, West China Hospital, Sichuan University, Chendu, Sichuan, China. yingbinwu@scu.edu.cn.
Abstract
PURPOSE: Circulating tumor DNA is more and more accessible for patients who cannot undergo biopsy. No consistent conclusion has been reached on whether frequency and proportion of mutations defined by ctDNA profiling can predict therapeutic outcomes. METHODS: One hundred patients with non-small cell lung cancer harboring activating EGFR mutations (exon 19 deletion, L858R and T790M mutation) were collected in West China hospital from December 18, 2017 to December 31, 2019. We retrospectively analyzed the frequency and proportion distribution of ctDNA mutations and its relationship with tyrosine kinase inhibitors therapeutic outcomes. RESULTS: Patients with lower frequency of sensitizing EGFR mutations (< 3%) had a longer progression-free survival (PFS) time than those with higher frequency (15 months vs. 10 months, p = 0.028). Moreover, patients with the lower ratio of T790M mutation frequency and the maximum-somatic-allele-frequency (T790M/MSAF < 30%) had a less prolonged PFS than those with higher T790M/MSAF (7 months vs. 15 months, p = 0.013). CONCLUSION: The frequency and proportion of ctDNA mutations are worth clinical attention in the prediction of therapeutic outcomes.
PURPOSE: Circulating tumor DNA is more and more accessible for patients who cannot undergo biopsy. No consistent conclusion has been reached on whether frequency and proportion of mutations defined by ctDNA profiling can predict therapeutic outcomes. METHODS: One hundred patients with non-small cell lung cancer harboring activating EGFR mutations (exon 19 deletion, L858R and T790M mutation) were collected in West China hospital from December 18, 2017 to December 31, 2019. We retrospectively analyzed the frequency and proportion distribution of ctDNA mutations and its relationship with tyrosine kinase inhibitors therapeutic outcomes. RESULTS: Patients with lower frequency of sensitizing EGFR mutations (< 3%) had a longer progression-free survival (PFS) time than those with higher frequency (15 months vs. 10 months, p = 0.028). Moreover, patients with the lower ratio of T790M mutation frequency and the maximum-somatic-allele-frequency (T790M/MSAF < 30%) had a less prolonged PFS than those with higher T790M/MSAF (7 months vs. 15 months, p = 0.013). CONCLUSION: The frequency and proportion of ctDNA mutations are worth clinical attention in the prediction of therapeutic outcomes.
Authors: Sarah-Jane Dawson; Dana W Y Tsui; Muhammed Murtaza; Heather Biggs; Oscar M Rueda; Suet-Feung Chin; Mark J Dunning; Davina Gale; Tim Forshew; Betania Mahler-Araujo; Sabrina Rajan; Sean Humphray; Jennifer Becq; David Halsall; Matthew Wallis; David Bentley; Carlos Caldas; Nitzan Rosenfeld Journal: N Engl J Med Date: 2013-03-13 Impact factor: 91.245
Authors: Geoffrey R Oxnard; Cloud P Paweletz; Yanan Kuang; Stacy L Mach; Allison O'Connell; Melissa M Messineo; Jason J Luke; Mohit Butaney; Paul Kirschmeier; David M Jackman; Pasi A Jänne Journal: Clin Cancer Res Date: 2014-01-15 Impact factor: 12.531
Authors: Muhammed Murtaza; Sarah-Jane Dawson; Dana W Y Tsui; Davina Gale; Tim Forshew; Anna M Piskorz; Christine Parkinson; Suet-Feung Chin; Zoya Kingsbury; Alvin S C Wong; Francesco Marass; Sean Humphray; James Hadfield; David Bentley; Tan Min Chin; James D Brenton; Carlos Caldas; Nitzan Rosenfeld Journal: Nature Date: 2013-04-07 Impact factor: 49.962
Authors: Geoffrey R Oxnard; Kenneth S Thress; Ryan S Alden; Rachael Lawrance; Cloud P Paweletz; Mireille Cantarini; James Chih-Hsin Yang; J Carl Barrett; Pasi A Jänne Journal: J Clin Oncol Date: 2016-06-27 Impact factor: 44.544
Authors: Evan J Lipson; Victor E Velculescu; Theresa S Pritchard; Mark Sausen; Drew M Pardoll; Suzanne L Topalian; Luis A Diaz Journal: J Immunother Cancer Date: 2014-12-16 Impact factor: 13.751